NASDAQ:PHIO - Nasdaq - US71880W5013 - Common Stock - Currency: USD
1.67
-0.05 (-2.91%)
The current stock price of PHIO is 1.67 USD. In the past month the price decreased by -28.63%. In the past year, price decreased by -77.51%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Phio Pharmaceuticals Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Marlborough, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2012-05-10. Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The firm's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The company is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The firm's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
PHIO PHARMACEUTICALS CORP
11 Apex Drive, Suite 300A, Pmb 2006
Marlborough MASSACHUSETTS 01752 US
CEO: Gerrit Dispersyn
Employees: 9
Company Website: https://phiopharma.com/
Investor Relations: http://investors.phiopharma.com/investor-relations
Phone: 15087673861
The current stock price of PHIO is 1.67 USD. The price decreased by -2.91% in the last trading session.
The exchange symbol of PHIO PHARMACEUTICALS CORP is PHIO and it is listed on the Nasdaq exchange.
PHIO stock is listed on the Nasdaq exchange.
7 analysts have analysed PHIO and the average price target is 36.72 USD. This implies a price increase of 2098.8% is expected in the next year compared to the current price of 1.67. Check the PHIO PHARMACEUTICALS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PHIO PHARMACEUTICALS CORP (PHIO) has a market capitalization of 7.98M USD. This makes PHIO a Nano Cap stock.
PHIO PHARMACEUTICALS CORP (PHIO) currently has 9 employees.
PHIO PHARMACEUTICALS CORP (PHIO) has a support level at 1.66 and a resistance level at 1.84. Check the full technical report for a detailed analysis of PHIO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PHIO does not pay a dividend.
PHIO PHARMACEUTICALS CORP (PHIO) will report earnings on 2025-03-31, after the market close.
PHIO PHARMACEUTICALS CORP (PHIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.28).
The outstanding short interest for PHIO PHARMACEUTICALS CORP (PHIO) is 2.09% of its float. Check the ownership tab for more information on the PHIO short interest.
ChartMill assigns a fundamental rating of 3 / 10 to PHIO. While PHIO has a great health rating, there are worries on its profitability.
Over the last trailing twelve months PHIO reported a non-GAAP Earnings per Share(EPS) of -13.28. The EPS increased by 12.83% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -126.5% | ||
ROE | -150% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to PHIO. The Buy consensus is the average rating of analysts ratings from 7 analysts.